Navigation Links
Neurocrine Biosciences to Present at the 30th Annual J.P. Morgan Healthcare Conference
Date:1/6/2012

SAN DIEGO, Jan. 6, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 30th Annual J. P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, California.   

The corporate presentation will review the Company accomplishments in 2011, as well as outline the corporate plans for 2012 and beyond.

Specifically, the Company will discuss the recent very productive Type C meeting that was held with the FDA on elagolix for endometriosis, one of the outcomes of which was the decision to file a Special Protocol Assessment (SPA) with the FDA. The expected NDA filing of elagolix for the treatment of endometriosis is in 2015.

Additionally, the presentation will cover the Company's VMAT2 program for movement disorders, including the status of the current Phase II study assessing the impact of NBI-98854 in patients with tardive dyskinesia. This study, which began in the fall of 2011, has recently completed enrollment and will report top-line data in the first quarter of 2012.  The Company also recently received a notification of allowable claims for its NBI-98854 European Patent Application from the European Patent Office, and has begun planning for larger Phase IIb trials, to be launched in mid-2012, for up to three months of continuous treatment with NBI-98854.

 

The live presentation takes place on Thursday, January 12, 2012 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.  A copy of the presentation materials will be filed with the Securities and Exchange Commission on or before Monday, January 9, 2012.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600.  Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, tardive dyskinesia, uterine fibroids, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

 


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurocrine Biosciences to Present at the 23rd Annual Piper Jaffray Health Care Conference
2. Neurocrine Biosciences to Present at the 2011 Credit Suisse Annual Health Care Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2011 Financial Results
4. Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement
5. Neurocrine Biosciences Announces Elagolix Scientific Presentations at the 67th Annual Meeting of the American Society for Reproductive Medicine
6. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
7. Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids
8. Neurocrine Biosciences To Present at the Stifel Nicolaus 2011 Healthcare Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2011 Financial Results
10. Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis
11. Neurocrine Biosciences to Present at the Jefferies 2011 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  Henry Schein, Inc. (NASDAQ: HSIC ), the ... to office-based dental, animal health and medical practitioners, announced ... acquire a majority ownership interest in Dental Cremer S.A., ... Brazil . --> ... is the dental distribution business of Cremer S.A. With ...
(Date:2/4/2016)... , Feb. 4, 2016 For hospitals ... or those already participating in the program, the Health ... referred to as the , Mega-Guidance , could have ... guidance is published in September 2016. Essential ... and Service Marketing , summarizes the Mega-Guidance,s key proposed ...
(Date:2/4/2016)... , Feb. 4, 2016   Bernstein Liebhard LLP ... in the United States District Court for the District of ... (the "Class") consisting of all persons or entities who purchased ... (NASDAQ: INSY ) from March 3, 2015 through January ... certain of its officers with violations of the Securities Exchange ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University ... Allen have signed a joint enrollment and degree completion agreement. The agreement, ... and baccalaureate degrees at FHU|Dickson. , The agreement allows students to be ...
(Date:2/5/2016)... Illinois (PRWEB) , ... February 05, 2016 , ... ... and independent PROSHRED franchises from across the country gathered at the La Valencia ... recognize top performers. PROSHRED Chicago was named the year’s most outstanding franchise, ...
(Date:2/5/2016)... ... ... Boar’s Head Brand®, one of the nation’s leading providers of premium delicatessen ... stress out of your party preparation – follow these easy, yet delicious recipes with ... game. , “The key to hosting a successful game-day party is creating a flavorful ...
(Date:2/5/2016)... ... February 05, 2016 , ... Stuart Bentkover, MD, FACS is thrilled ... provide the most effective tattoo removal today, Dr. Bentkover is the only doctor in ... Cynosure, the PicoSure has been approved by the Food and Drug Administration (FDA) as ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Health and ... more relevant to individuals in the event they are experiencing an illness. Migraines are ... Those Americans that are afflicted with migraines would not wish the pain on their ...
Breaking Medicine News(10 mins):